Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
PubMed 22962027 TB-4 Phase 1 human safety first-in-human randomized, double-blind, single- and multiple-dose Phase 1 of recombinant human thymosin 4 in healthy volunteers, no serious adverse events: PubMed 34346165
(GP-diagnosed, serum level below 150 pmol/L): Three injections over the first two weeks, then 1000mcg every two to three months
Information from the manufacturer Hevert to the website Other products from Hevert For risks and side effects, read the leaflet and ask your doctor or pharmacist.
An intradermal skin test should be performed if there is a hypersensitivity risk
LPI Recommendation A varied diet should provide enough vitamin B 12 to prevent deficiency in most individuals 50 years of age and younger
